Patients with myelofibrosis (MF) may experience worse outcomes after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to a study recently published in Therapeutic Advances in Hematology. “The present study confirmed dismal outcomes in the older [myeloproliferative neoplasm] patients and in those with higher comorbidity burden, (ie, cardiovascular or pulmonary disease or diabetes),”…
Allogeneic hematopoietic cell transplantation (HCT) appears to be superior to the best available nontransplant therapies (BAT), such as fedratinib, momelotinib, ruxolitinib, splenectomy, and splenic radiation, following first-line JAK inhibitor (JAKi) therapy failure in patients with symptomatic myelofibrosis (MF), according to a recently published study in the American Journal of Hematology. Since the US Food and…
Roxadustat appears to be a safe and viable option for patients with myelofibrosis (MF) who develop anemia after receiving ruxolitinib, according to a letter to the editor in the Annals of Hematology. Janus kinase (JAK) inhibitor therapy has been the mainstay of treatment for over a decade; however, anemia is a known adverse effect of ruxolitinib,…
Following the 2016 reclassification of myeloproliferative disorders by the world health organization (WHO), a significant percentage of patients with myelofibrosis (MF) does not receive early prognostic risk assessment, furthermore over a third of patients diagnosed with essential thrombocytopenia (ET) do not undergo bone marrow examination despite meeting at least 1 WHO criteria for MF, according…
The production of interleukin-8 (IL-8) by malignant megakaryocytes appears to promote emperipolesis between neutrophils and megakaryocytes, which contributes to developing a tumor growth factor beta (TGF-β) microenvironment that favors fibrosis, it could play a role in myelofibrosis, according to a recently published study in Experimental Hematology. Emperipolesis, the passage of 1 cell type into the…
A better understanding and characterization of the disease process in myelofibrosis could be achieved by analyzing imaging results, according to a study recently published in Tomography. “As a single technique, we feel that T1-weighted MRI best reflected the response to ruxolitinib therapy,” the authors wrote. Read more about myelofibrosis diagnosis This prospective observational study included…
Early initiation of ruxolitinib (within the first 12 months after diagnosis) appears beneficial for patients with myelofibrosis, improving overall survival and reducing cytopenia events, according to a recently published study in Cancer. The efficacy of the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib has already been demonstrated in the randomized, phase 3, controlled myelofibrosis study with…
Please login or register first to view this content.
